-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, W0lOe68kyeFO2jyGGLGQjhYjFcHg+Qi6SidTUnJQx4+jRTAksCzvrI1a5l570Wan tdIrpgBINzKCfPx58WWkMg== 0001362310-09-004347.txt : 20090326 0001362310-09-004347.hdr.sgml : 20090326 20090326151450 ACCESSION NUMBER: 0001362310-09-004347 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20090326 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20090326 DATE AS OF CHANGE: 20090326 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QLT INC/BC CENTRAL INDEX KEY: 0000827809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17082 FILM NUMBER: 09706473 BUSINESS ADDRESS: STREET 1: 887 GREAT NORTHERN WAY STREET 2: - CITY: VANCOUVER STATE: A1 ZIP: V5T 4T5 BUSINESS PHONE: 6047077000 MAIL ADDRESS: STREET 1: 887 GREAT NORTHERN WAY CITY: VANCOUVER STATE: A1 ZIP: V5T 4T5 FORMER COMPANY: FORMER CONFORMED NAME: QLT PHOTO THERAPEUTICS INC DATE OF NAME CHANGE: 19960618 FORMER COMPANY: FORMER CONFORMED NAME: QUADRA LOGIC TECHNOLOGIES INC DATE OF NAME CHANGE: 19941201 8-K 1 c83153e8vk.htm FORM 8-K Form 8-K
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 26, 2009

QLT Inc.
(Exact name of registrant as specified in its charter)
         
British Columbia, Canada   000-17082   N/A
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
     
887 Great Northern Way, Suite 101, Vancouver, B.C.
Canada, V5T 4T5
    
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (604) 707-7000
 
Not Applicable
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

1

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers

On March 26, 2009, QLT Inc. announced the appointment of Ms. Kathryn Falberg to its board of directors and audit committee.

Ms. Falberg is currently Chief Financial Officer and Chief Operating Officer of ARCA biopharma and has over 20 years of experience as a financial executive and corporate director. Ms. Falberg’s career includes seven years at Amgen, one of the world’s largest biotechnology companies, where she served as Senior Vice President and Chief Financial Officer, as well as Vice-President, Controller and Chief Accounting Officer and Treasurer. She also served as Chief Financial Officer of Inamed, a medical device company which was later acquired by Allergan. Ms. Falberg currently serves as Chair of the audit committees for Halozyme and ESS Technology. Former directorships include Human Genome Sciences, Fresh Del Monte and VISX.

This appointment brings the number of directors on the Board to seven.

The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

     
Exhibit No.   Description
99.1
  Press Release dated March 26, 2009

 

 

2

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

QLT INC.

Date: March 26, 2009

By: /s/ Cameron Nelson                           
Name: Cameron Nelson
Title: Vice President, Finance and Chief Financial Officer

 

 

3

 

EXHIBIT INDEX

     
Exhibit No.   Description
99.1
  Press Release dated March 26, 2009

 

 

4

EX-99.1 2 c83153exv99w1.htm EXHIBIT 99.1 Exhibit 99.1
Exhibit 99.1
news release
QLT NAMES KATHRYN FALBERG TO THE BOARD OF DIRECTORS
     
For Immediate Release   March 26, 2009
VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) (“QLT” or the “Company”) today announced the appointment of Ms. Kathryn Falberg to the Company’s board of directors and audit committee, effective March 25, 2009. Her appointment brings the board membership to seven directors who will all stand for reelection at the Annual General Meeting of Shareholders on May 5, 2009.
Ms. Falberg is currently Chief Financial Officer and Chief Operating Officer of ARCA biopharma and has over 20 years of experience as a financial executive and corporate director. Ms. Falberg’s career includes seven years at Amgen, one of the world’s largest biotechnology companies, where she served as Senior Vice President and Chief Financial Officer, as well as Vice-President, Controller and Chief Accounting Officer and Treasurer. She also served as Chief Financial Officer of Inamed, a medical device company which was later acquired by Allergan. Ms. Falberg currently serves as Chair of the audit committees for Halozyme and ESS Technology. Former directorships include Human Genome Sciences, Fresh Del Monte and VISX.
“Kate brings a wealth of experience and we are pleased to welcome her to our board,” said Boyd Clarke, QLT’s Chairman of the Board. “Kate brings a robust financial and strategic skill set and strong industry background in biotechnology. We believe that QLT will greatly benefit from Kate’s operational and financial experience.”
Ms. Falberg received her B.A. and masters in business administration from the University of California, Los Angeles.
About QLT
QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the field of ophthalmology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel® and punctal plugs with drugs, to create products such as Visudyne® and Eligard®, and future product opportunities. For more information, visit our web site at www.qltinc.com.
Page 1 of 2

 

 

 

QLT Inc. Media Contact:
Vancouver, Canada
Karen Peterson
Telephone: 604-707-7000 or 1-800-663-5486
Fax: 604-707-7001
The Trout Group Investor Relations Contact:
New York, USA
Christine Yang
Telephone: 646-378-2929
or
Marcy Nanus
Telephone: 646-378-2927
QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.
Atrigel is a registered trademark of QLT USA, Inc.
Visudyne is a registered trademark of Novartis AG.
Eligard is a registered trademark of Sanofi-aventis.
QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol “QLTI” and on The Toronto Stock Exchange under the trading symbol “QLT.”
Certain statements contained in this press release, which are not historical facts, are “forward-looking statements,” of QLT within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute “forward-looking information” within the meaning of applicable Canadian securities laws. Such statements include, but are not limited to: statements which contain language such as “expects,” “will,” “plans,” “estimates,” “intends,” “believes” and similar expressions that do not relate to historical matters. Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from the results expressed or implied by such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: risks and uncertainties associated with the timing, expense and outcome of research and development programs and commercialization of products (including the difficulty of predicting the timing and outcome of the synthetic retinoid drug development efforts, clinical testing and regulatory approvals or actions); uncertainties regarding the impact of competitive products and pricing; risks and uncertainties associated with the safety and effectiveness of our technology; risks and uncertainties related to the scope, validity, and enforceability of our intellectual property rights and the impact of patents and other intellectual property of third parties; and other factors as described in detail in QLT’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are based on the current expectations of QLT and QLT does not assume any obligation to update such information to reflect later events or developments except as required by law.
Page 2 of 2

 

 

GRAPHIC 3 c83153p8315301.jpg GRAPHIC begin 644 c83153p8315301.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(" M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@," M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$! M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,` M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1 M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%4!IP,!$0`"$0$#$0'_V@`, M`P$``A$#$0`_`/W\H`0D`$D@``DDG``')))Z#%`'RS\1?VW/V4/A3>7&F^-? MCGX(LM2M':.[TO1;F]\8:I9RKPT-YIO@RQU6YM9@>L,_#NE6H&3U,P'/6@#[&TK M5M*US3[35M#U/3]8TJ^B6>QU/2KVVU#3[R!\[9K2]M))(;B)L'#QNP/K0!H4 M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`! M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!F:UK.E>'- M'U37]=U"UTG1-$T^\U;5M4OIEM[+3M-T^WDN[V]NIW(6*WAMHI)'<\!4)H`_ M'-=9^.O_``4S\2Z[;>#?$WB'X&?L5Z#J=SH"2"S`/MCX;?L`_LC?"[3K6RT?X*^$M?N[=`LNM^.[& M/QKK-Y)G+SSS>(%N(('8]4M+>VB'18U'%`&3\1_V0?V&OB`MQX=\1?#CX1Z% MK$Z&"*7PG/HW@7Q-:RGA'MSX!+PV.H_M M'>)+73?%EY#E;FS\-1^)?#]CIZ`HX865S?/J4UROW7@T:2-LK(P(!^C>GV?P MW_9P^#UO9I)9>$/AE\)O!V)+B;"0Z=HFA61DN+N3<7%Q+:W-N]Y$7B*3%[I-,MI"UO%!J,]O/*H!Z)=?\`!&;]F*XTAK:/Q?\` M&&/7FCR?$RN)8R9(VD7[,`-O(P/\`@DW\:+#P/^U!XP^#7A_5-0NOAC\6;76[GPI! MJ_[B\@UGPO%=:UH%U=VZDQ0ZK+X7CU6RO/)^66:&WVLR0QF@#^F&@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`_$7]K^]30_^"J_[&6L: MN?)T.?PGX1TBSEF;;;+K-]XX^)>F@+N^59A"<@ M'WOXD\1?#+]E/X%2ZOJ7E^'OAM\(O!]C8VUK9PQ_:'M-+M[?3-*TNPMP8UNM M8U&]-M;QJS+YUS>AI'&]W`&WE8_*+P]XS_X*6_MNVTWQ$^$^O^&?V:O@Q>75 MW_PA2:A)]EU;Q!8V\I@6\.HQ^'M5U;509(W5[Q(M+L'=9%MHY!&Q(!\Z?&SX MU?MD?LZ:?K_P(_;9TVQ^,?P?^*_AW6]$LO$]O'I\]TDODQ_9=?\`!WBJST_3 MWDUS0]4.G:B-,UVT$I:&)D,"R).0#XI_X)WV]Y-^VE\`8[`.TL?B^\GD\L$$ M65OX_9L`X3[#'/NSVS0!_970`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`% M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0` M4`%`!0`4`%`!0`4`?E#_`,%5_P!GGQ%\1/AIX:^.G@![F/QS^SV^H>(Q!I\3 M-J-YX=GO]#O[Z]M63GS]"DTDZLHP2(DNRN6P&`/D[]K/XQ6O[8W[$'PX_:`\ M"S0Q_$7X`^.-`U7XH^&;3$E_X5OKZT&E:CK"6:_O!H4^MQ:+J%K*VG:Q\2O!]I\2-(M95-QX;U^U M\/>(7OM`U>)&+0Q0^(%MI(6D`6:.2PN$^6:,D`_7SX.ZUHFM?`/X'7\%6IG-OI(6U\/VUOI^EWU"RAE^(?@!_#LFIZ= MXNUBUL;=V?Q)X>MK::ZMY-0T47:>5=Q37$4"JWE`'SY_P1G_`&?=3UKXC>*? MVAM:L);?P[X(TV_\'^$IYXBB:CXNUR&)-:GM&=?G33-`DD@E*\>9K\:@[HG" M@'](5`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4` M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!'+%%/% M)#-&DT,R/%+%*BR12Q2*4DCDC<%71E)!4@@@D'@T`?@E^TY_P3S^+WP4\:>) M/C7^Q4T]YX>\26>IVOC;X+VRV]TS:/K2O'KV@:?H%^#9>-/!%[%-,&T&='N; M8.%LTF"1&T`/PZF\1_$3P!'XX\"2#7?!FG>+4BLO&?@/4;2^L;*X6ROTU'38 M]0T+64+Q7FG7T,3.%+M9B$RL09`[8-`'TM\>/" M?Q[\6?"?P#^W1JOA;QI\./BEHFNV_A+XE>*H-(G\$WGB26W$2_#_`.,>BV]C M%9RZ>+JREC\-:C/%#;Q/=:9I\T09=0DV@'UW^Q9_P58BT6PL?`'[1GAV*PT? M[3*;?XO>$/#D=E:)>7L[SW]_X^\/Z'8I#)<7%W-)<7.LZ;#YLDDKR7-H[O)< MT`?O;X:\3^'/&.AZ=XE\):[I/B/P]JUNEWI>M:'?VVI:7?6\@RLMK>6&[ M+*J2`'W=X;^*]WIG[8_Q3\,^-O'$/ASPO;?`;X1:YI7A7Q!XEM=/T33?$FK: MUXL77+C3+2_NHHC?M%;6T4\T*EF6&+><;*`/,O'_`,/]4O?VR_ASX*L?CE^T M!IW@WXD_#OXE_$[5=&T'XO:[8Z1;ZQX?U[PNFC6OA^WMLQ:;X;%MK%XOV"'= M&Z&(!@J'>`>X_MO>+?$_@CX%+K?A'Q!JWAG5Q\3O@YI?]J:/>RV%]_9VK_$S MPQIFJV9N(&5OL]WI]S<6\R9Q)',Z,"K$$`X3Q9^UQXZ\.?%?Q7X8M_A[X4NO MA_X'^//P?^!^N:W-XLU*W\6WMY\8M(\-W>FZUI.B)H+V*0:5>>(8Q<17.H*U MQ$F(=KAB`-O([+X5_M,:_P"/_'&JQ:GH_P`-O#7PU&N_%WP]H]W>?$FVMOB7 M9R_!O76T'7=9\1>"-0TZW1-%NY+>[NB]E>2MI=N;-[_Y;U&4`^O+&^LM2LK3 M4M,O+6_TZ_MH+VPO[&XANK*\L[J)9K:[M+JW=HKBVFA=)$EC9E=7#*2"#0!: MH`*`/*/COXHO_!/P5^+'BW2M9C\.ZKX<^'GB_6-*UV73GU:/2-3L=#O9]/U! M]-1&^V+!>+#(8RK*=OS@H&H`_,VS^)GQF709_AW-XE^)'_"07/QL\+:,O@=_ MBUX+E^)$GAO4/@;J?CS4+*S_`&@HK0>'+&UN=?L1K:6I*W2VEA/I<3QC4(8T M`V\K'L/AO4?%WQ1T7]D=].^+_P`23\0?'V@Z)XH\>7'AWQ)-H?AQ/`'P],=Y MXVU75O#4%G]EGU36=;N]%\)_;XXX8KJ36)KVU"QVJJ`-CZ$^/?B'56\=_!OX M9/X[U/X5^#?B'<>,WU_QGH=Y9Z/KNIZMX:T[2KOP[\/-%\27]O-%X=OM:%]J MNH-/$BWD\'A:>ULY(WG=U`V\C@_"/QJOM!@TKX>_#VQ\_%SQE\,G/ MQP\7Z1INH>']4\/?#D?$<_:/$OAS2]9DUOP\^F?9#;R.EU?@ZH4F.8-D8&QJ MZ=^U1K5[J_CF*7X=VNC>%?"%[.X\,03W[7TFI+>06NJ6VFSA&\ MB=('B9V`V\AWQB\6_&+0/CYX6_X5I, M_#^D7J>'[R9D.F^-[&QO9+G2V=Q;W)W\01 M>!7TWQ]=>.?C'\3(?`ESXW\1W'@GP[X=\(>!O!_@/5-3T.[NCH%]J%KK%OJ. MM3V\>C?VH>`/VB/$_Q1UO3K+P9\/-,32!\._!?Q"U[ M4/$'C,V%U90>+[OQOI0TG2+33?#M_'K4EOJ7@YW2_P#/MK6ZM+M9XFRT:.`> M"0_M-_%^2P^'7Q7NO#?A.73KG]G3XK_%OQ3X"T;QW?Q:+)H?A?6/AW?PZA:W MUUX6DED\90Z/>ZK:06,J):I)?/YEYM;Y`-O(]CNOVJ-3'C#QOI>E?#'5-1\' M^"#XETN_\3&]OK6XAU[P[\.V^(GFZA;2:$=.L_#U["8=+@EBU:YOFGN8KG[" M;-S(@!4UO]I/XEZ+X?\`!VKR_"KPG]L\9_#SQU\6+'3V^)5X$LO!O@?PQX0\ M37%K>7:>!R'\2W:^)9[)((4DM(Y+6.9KMHI&$8&WD7_C;\8]<^&>C?#;X^:3 M%KFJ^`]:\/7?A[7?`\$9NC-K?C[2;+4_A3J:VULC-%J3^-;73?"TDT;E`GC< M.X*VP90#QCPY\0OC/X/UNR^!OQ"\9W.H^+?AHNI?'WQ]\1M3N(/#6AZ]\(8/ M#&KB5+>62/0O!LTIC?S>0#N[3]LG4SI>B MRW'PQGN-5\3^-/%7PD\,1:5JNK?V;K'Q;T+6M'MM'T&635O"UC?:)H6L^&M3 MO]>34=1L;>2VM_"^K)-;$I"\X!]V#.!NP&P-P&2`<'?#FOWGC[XEZ9X%N1XE\17GANRTVUO="\0:Y M+>0W%CHNI/-=&+098T4P[0TB@AMWR@'J^NZM%H.A:QKLT,US#HVDZAJTMO:J M9;BXBTZSFO'AMD`S)-(D)5%`Y9@,`O'/ MQ.^(7P;UKQ3K]GJ7@N;3/!WPG^-ESK/_``C5K\-=9\/7&HPZ`'C\*KX=$FNA MM62^U:346427D"6X!#XR_:.^,7A_X->%[70+?Q]K\>G?$C6-$UOXW:5X1'B. M#7?!'A#X[CX?:%ID5YIJQ6?_``E_BC0[;;/J:P"#;#*\"_:M7MC;@'U;^U+/ M>3?#FRN?"OC+QUX8\=ZIK5EX)^'>G>"_$H\.2:MX_P#&LMMI>C6_B2(65U]J MT[1P.(S%9:3J+,0.0`>%W?C+X@>&?BO;V#?%3Q1J%UX!^,7P-^!%IX$ MU"YTK[/X\\(>,O`6BZCXK\>^(-/6Q%U?^*+J^U37-:BU2"6**UC\&S0(GE?: MPX!Z_P#`C3]6_P"%G?&+7X?B7\1?$WPS\+W]E\,]`M?'7BJ+7M/U#QQIEPU_ MX^U[3GDT^V:WMK'4+[2O"]O&LDB?:=%UCJSKM`/(?B1K/CGP9XL_:/\`''P[ M^(WQ(U71O@S\*O$5]JNE>(O$$?B#PA#\5O&=J->TVTTW19-,`BTSP/X.$6K2 MV8G96/B6PAD!%FP8`Q4\6>+U\;#X"CXX>-I/AY-\5-/TE_C5_;_A\>-EM[GX M"7_Q0F\$P^,UTG^SXI9?$UI;WZS"U,R:=I^&K']DNWTSPK8-H^FZ%\5K;XT_$>7P?XV\3:WHMQ8M-JHU31$+: M<+*6WBTR>T>YC!#.*`/U-H`*`"@#C/%7PX^'OCE%C\;>!/!WB]$78B^)_#.B MZ[L3^[&=4LIS&/\`=Q0!B>&?@G\&_!=TM]X0^%'PW\+WT;;TOM`\$^&])O4; MLRW=CIL4RD=L.*`.YUO0M$\2Z5>Z#XBTC3->T/4H?L^HZ/K-A:ZGI=_!O63R M;RPO8I(+F+S$1MLB,,HIQD"@!ECX>T#2[!=)TS0]'T[2XT\I--L=,LK2P2/& MT1K9V\"0JF!C:$QB@-O*PW1?#?A[PU'1>)?@#\#O&.O7GBCQ5\(?AOX MA\2W]J;*^\0:OX-T"]UJ[MR@C59]3GL6N))$C`5)6D,B!0$90!@`L^+_`(%_ M!;Q_J::UX[^$WPY\8ZQ':06":KXH\&>'M=U%+&VWFWM%O-3T^:5;:(RR;(P^ MU?,;`&XY`.S3PEX6AU32-;B\.:''K/A_29]`T+54TNR34=&T.Y^S?:-'TN\6 M$2V&F2_8[3?;0LD;?9HLJ?+7`!/KWASP_P"*-/\`[)\3:)I6OZ6+NQO_`.SM M9T^UU*R%[IMW%?Z==_9;R*2/[3:WL$$\,FW=')"CH0R@@`RKGX?^!;NXO[N[ M\'>&+FZU37=&\4:G<3Z'ILL]_P")?#T=M%H&OWLKVQ:YUG3H[.T6UO)"TUN+ M6(1.HC7`&WD9(O&MC=:7XOUN/POHR:KXFTZ_C M\K4+'7+X68EU*TNXPJW$4[.L^U?-#[1@`[32M*TS0M,T_1=%T^RTG1](LK73 M=*TK3;:&RT_3=.LH$MK.QL;.W1(K6T@MXXXHX8T5$1%50``*`+]`!0!7NK>U MN[:XL[V""YL[J&2UNK6ZBCFMKBWN4,,UO<03*4FAEC=D:-U*L'*D$'%`'FZ_ M!3X.1^%)?`*?"WX>Q^"[G4/[8F\)+X0T!-`FU5""-4?25L1;OJ"_*HN3&9%4 M*@8*`*`V\CMK#PWX>TJ>UNM,T'1M-N;#1X/#UE/8:996^#+O7/$EA-I7B#5KGPUI$NHZUIUS#';W-IJ=V]H9 M+V&:WAABD$K-O2")&RL:A0!(/A-\,+2'2+>V^'O@V"'P_P"()?%>AQQ^'-*1 M=(\37!1KC7].`M?]#U>9HXVDNHMLLC(K.S,H(`.ODTS2$U--?EL-/36(=/DT ME-8>W@74(]+GN8KR;3EOF7S4LI+N"&9H0X1I(DHZ?I?@+P580ZE:ZY;:K967AW1K>.\ ML?%3VS^(K6\MH;4"6RU1[*T-U"ZF.X-K%YBMY:X`)[GX8?#B\U]_%=WX#\(7 M/B5],?19->N/#NE2ZL^DR6,FEOI[W[VIF>U;3)IK,H7(^SS/!_JG*$`V;CPE MX6N8K*"Y\.:'<0Z9H]_X>TZ*;2[*2.PT'5+:VL]2T:T1X2+;2[JTLK.&:UC" MQ21VL2.I6-0`#0.E:2;&WTAM.T]M-LAI_P!DTU[2W:RM!I)OM6EO]IN2UK+NB/VB0E?G;(!YC;_!'P/I?C#PAXFT33].\.Z5X/D\2 M:MIWA/0]*T[2]%O?&GB/3++07\:ZE]FB1[W7+/PQ!J>FV[,/ECUN\D9F?84` MV\K'K_VBW`#>?"%W%`?-0#>.2H.[&[!Z=:`'I)&Z[HG1USC*,K+GN,J<9Y_6 M@!'ECBQYDB1C(`WNJ'8&VEO-3:&_NEMV`WM0!- M0`4`%`'->+/"7A+QGI!T7QGX?T3Q'HJW5K??V?K]A::A8QWMG*);.[2*[C9( MKJ*7E)5VLNX@'#$$`Z,(JJ$555%4(J``*%`P%"C@*!QB@#S6T^#?PBTK0/$_ MAFQ^&G@.P\->,+A[[Q;HEMX6T2VTC7[@L)?M.LV4=FL-Y)&X#QM*K>4RAH]A M&:`V\CJ%\(>$XO#EGX1C\.:%'X4TZ'3H;#P['I=E'H=E!I%Q;WNE1VNF)"+: M".TNK2UFA"1J(WMXW7#("`"-/"7@VQN8KU/#WA^UNT\07_BN"Z.G6,=Q'XGU M2QETS4M?AE:(,FLW.G7,]K+=H1*\,[QLQ1R"!MY6(9_`_@:\\7:?X]N/"GAF MY\<:=IL^FZ7XMFT?39?$EGI&1H'AZ30#J']K-H<>GV!TPZF-:'B,ZBU@D?E?;/\`A(,:B9BF\W1\ M\DR'=0!>M-'\.6B:O:66F:-;QZ[>WE_KMK;VEG&FKZA?P1V^H7>JPQQ@7UU< M6T$44LDX=G2%57P4_P_'PU\`K\/VOSJ;^$AX8T1?#)U/[0) MSJ#:4+3[+]N%PH/G[-XVA=V!B@#V\W3+=8^%CMVC5`3M"Y.0#LZ`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#E/'7A#3?'W@SQ1X)U9YX=.\4Z%J6AW M-Q:2-#>6:ZA:R6Z7UC,C*T%]:RNEQ#*I!26"-@05H`_.G_A/OC#I/A;Q1\9? M&B:MX1^(GAD6/[.WA"WG\,Q^(+'6M9\'VVKZKX]\9K:7NKZ;I^E:#XU\::38 MI;ZK<3.XL/#]I;6L4MYJ5NK`'HFB?'OXRZ_KWAK7[5-&@\'W-[^S)8ZAX8A\ M(:G++J'_``NW1\^,+JW\22Z@LEBGA_4IXI(E^RN(OLLL5\V)`8@!EA\?_B)- MX#UOQ%=^,O#]IXED\6^'-&\9^'6^'.LAOV;-%U/Q!JVEZMJ?B.V;41=^+S9V M]I:P?:)EM+;SI/[3).E$JH!3O/VF_B'X<\+P:UJ]QI-]HDF@?M#V?ACQY%X, MURPTWXC>(O`EAX5O/A7J.EZ,LL\M@VMO>>*[?[%&\D6J/X=FGTZ00/$I`V\C M5UCXX_M%Z7=^*-,TSP%!KLWAGX5W7QJLM530+^/3O$FC:QX,L[3PW\/[2*VN MVE_X2ZS^(@\375[%%^^DTG0+...-+C4@R@%3P5\8OC?XX_X0/P_I/C'P+(OB MCQGXUT>X^(FE>%)O$<5MH6B_#BW\6V+7^C6NHV>G:?KD?B&2:Q*+>R1/:F$2 M*E\)(Z`-S]J[Q%X?\:?`?X;>*-)U/PWKGA+5_BG\+M3FUCQ'HVNWO@N[T4ZE M/BUK M.0P3Z=;:_;P@Z%_:[6W[RSC^PMLF\@D!S0!\M_!;4OV:-$T_PK>'3=9M?VF= M'\.ZK?\`B^Z\3^%?'^L?%>V\>6?AB^G\;WGC-HH%DU2T:[35&CBDNUTNY#VT M6EL!):``%OP'\?/C%\1+/0=`T7Q!IVG7VH_%_P`1>$9/&=[\/X;J]'@=/@E+ M\3O#VKWOAS3O$XEU!&P!MY'GGASXQ>,XM6^)OQ!N?'QN_$VL?#CX`:3)/I'PSE M@T[P1XMUOQ'\4)-0\`7&DZ_KEG;64NFWEQ!;WFKZU>)+!#+'YT3S/;1L`??O MP>\6W/Q3^#7P]\8>(;&SAO\`QMX$T+4_$6EV\-Q%96^I:MI$)UW34MKPF>&& M*^DO+%O%\NL^+/!7Q!DUW0O`'[*O@OQSX4\)>,;Q; M^]3Q:OCO1[L^%O%\,5INFUF;PA\'I;?1IU&^5]1U?4"N9$4@`\N\*^#_``AX MH_9`^/'A9_`O@CQ5IWPE\-^+[;X<_$KPCX,UW0--^(6N6GPIL]_CC1]&UN6Y MU"+QE;:DG]G7U_9W5W!*/"/[8VE_M">#K/Q#XBL;BW\7V-W>:RWBW3H?&,WP4LY/*\#6IT6R_LK1=, M$UO'IR6OF20_:GMY&DNX)Y[@`C^+_@7X<>`OV>O@9?V&G>`O#NIZ1:6/Q#A^ M'/BCP%XE\0Z%\7O&!^%QT2Z\-:E8>&9(KN'Q3=SZO:O:74R7:1+X>N[W1-*N[K0)V5I]#N+BQ@FGTB9D`5I;.5VM MV*@`F$X`%`&W0`4`?+?[2N@:KXFU?]G;1(+H?\([>_'K1&\6Z--H7]MZ=K6F M:7X/\::_:0ZLIN(TM[&+4]'M61I@\:W4EG.09+6))`#Z.U^ZU&QT+6KW1['^ MT]6L])U&ZTO3=VS^T-1M[.:6RL=Q(V^?O`7C+Q-XA^$4VC M_$:S/B+PI!\3_@[X]_:+\=:/9?$!?[6A\8WVL'X@>!O'FD^(;"*Y@F\+:OH_ MA&+5M/T1'TNUT&>WMI(((89EE`V^1TGC"V^/#)+"XDBEFAN'MIM,$ZK M:V%Q#>`'UE^TM8^$OBYX#LO!ECX;TKQ7XV\1>.3\(]$U"ZT6;54^&VN:O:K+ MX^\4+=36J+:2^'_!UGJNH0W8VQ37EEI\*,SSJM`'@.J>&;3PS^T)IGAG2=+U M^V^(V@_%;X(Z5\)&B@U^>QLOV9=%\`:9IWCNUM]2"MIZ^&E>'QW%JL<\H>75 M)]-:56G>Q-`'M7P3\)?#SP9XR^,?QRM_"^F?#GPK?Z_8_"3P7!9Z-V\-RT'S:?H.DR[A%*S$`\P^(?PO.K>(OVH M_B7\)_!)\-:[X%^&OBOX?>%-0\-:7-I7B+QE\1?%FGP>*?B;XHTV2)(I=2U6 MTTJ;1]$TJZ02'^T)];\ARS@T!^!Y7'!\-!=&XCTW4A^P[_PN/3WN;%])\8CP MR=27X$WUO-<3Z2;7^U&\)_\`"S?[-24F`VQ\3+YCYF#O0&WD?17PQMO&T,O[ M#B^+X?$"ZS;^`_B]O6@GNA9V:2NIN;HVUK5&&?R[>5\;8V(` M+5`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`! M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!X'^T'I7Q@ MN/"^DZM\$-0\GQII&MQV;Z+=WJVFB:OH?BJUN/"NI7VHI(-DEQX;?5K7Q5:C M*EY/#+VPR+UE(!\^V7A#]L#1?A_XFU\^*+CQ'\3OA_XET3PY\._#M[JMO:^' M?BCX'\(0ZCX?N_%?C&*+]S;>(_%MIXBN]Z! MX,\<:C>^,K[Q=XZ^%EYX=TWX3V$^KP:;I?QKT;PS=W7B#7=7\)CSV+@'<_!71/VBO!>LZG;?&'6]=\?6.BOI?@/P;JV MD/IS0>)/^$F>?QEK_P`2_&>G-=6OV.UT.ZN['PE;B#S9DMM$GF2"0W[.`#YS MM;/XQZ_XAUGX;^)(OB=?^,V^'GPS\5^+M!\6:]::AX9U7Q=HG[17ABY\0^*? MAY;0ZF^G6'A>+0+"\:VCM8;$K9I;PRPM=+)D`]I\)>$OBYHGC#5[7[-\49\_ MM-:]XHU+5_$/B.WUGPI=_"S5O#7Q`;PVOA476JS-86=M<7?ARWO+.WM+22*: M.U0ATB8@#;RL1R^+-*OO&D7BJW\ M::JGQDT;X>:EJ%W'!H/B2;P.+(10P2V]LSHC6DT=_)YY`/=?%-UX_G^#C^&_ MASH'QALM<_L/1=675/$NI:*/'S>'QXYM(/%WAFS\0ZOKEV8?B9-X*CUE]+FO MBT4;7&GO+=I<*PC`/*/&^F_%>;2O#@\)Z?\`M*Q>&F\">)+;PA8V7BO2+3X@ MZ5\6)=?NY-(U#XK7VL^(7DU'PI_9WV!;+[;=ZC9PPQ7BZG:N\ML%`*'B[P%^ MTMJVHZS?_P#"4?$JSU"Y\90Z3)%X-\7P:1X:'A+_`(9L>XO]0\/Z7(P%A')\ M>+&R2*Z*I>(;B2-=EI<3%@-O*Q]N?#Y_$LG@+P1)XS1X_&#^$/#3^*TE6W61 M/$K:-9-KJ2+:$P*XU0W0(A)C!!V';B@#KZ`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`*']EZ8-3_MK^S[$:Q]A_LO\`M;[)`-2_LS[1]K_L B_P"W>7YWV'[5^^\C?Y?F?/MW -----END PRIVACY-ENHANCED MESSAGE-----